Hayley M. Sabol

Federal Grant PI

Researcher

UAMS

Last publication 2026 Last refreshed 2026-05-22

faculty

6 h-index 66 pubs 105 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Hayley M. Sabol's research focuses on understanding and targeting signaling pathways involved in multiple myeloma, particularly within the bone marrow microenvironment. Her work investigates how interactions between myeloma cells and bone cells, such as osteocytes, contribute to tumor growth and bone destruction.

Sabol has published studies examining the role of Notch signaling, specifically Notch3, in promoting myeloma progression and chemoresistance. She has also explored other signaling axes, including CCL3-HMGB1 and CXCL12, that regulate the tumor niche and influence treatment outcomes. Her research utilizes various models, including cell lines and mice, to dissect these complex cellular interactions. Furthermore, her recent work has extended to identifying senescent osteocytes as contributors to bone destruction in both myeloma and breast cancer metastasis, employing single-cell transcriptomic analysis.

She has received federal funding from the NIH/National Cancer Institute for her work on targeting Notch3 for multiple myeloma treatment. Sabol leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Aric Anloague, Olivia Reyes‐Castro, Japneet Kaur, and Elena Ambrogini.

Metrics

h-index: 6
Publications: 66
Citations: 105

Selected Publications

Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)

1 citation DOI OpenAlex
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024)

8 citations DOI OpenAlex
Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis (2024)

13 citations DOI OpenAlex
Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer (2024)

DOI OpenAlex
Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024)

3 citations DOI OpenAlex
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024)

10 citations DOI OpenAlex
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma (2023)

5 citations DOI OpenAlex
Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity (2023)

DOI OpenAlex
Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction (2022)

DOI OpenAlex
Abstract 5675: Pathological crosstalk between osteocytes and breast cancer cells in bone metastasis (2022)

DOI OpenAlex
Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction (2022)

15 citations DOI OpenAlex
Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity (2021)

32 citations DOI OpenAlex
The multifunctional role of Notch signaling in multiple myeloma (2021)

13 citations DOI OpenAlex